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Apostolakis et al. used the vitamin K antagonist (VKA) arm of the
AMADEUS trial to assert the superiority of the HAS-BLED
bleeding risk–prediction scheme over the HEMORR2HAGES
and ATRIA schemes (1–4). Deficiencies in their study’s design
nd analysis undermine this assertion.
First, their primary endpoint was clinically relevant bleeding (1)
when the appropriate endpoint is major bleeding. The bleeding
risk–prediction schemes, including HAS-BLED, were developed to
predict major bleeding to help guide the anticoagulation decision in
atrial fibrillation (AF). “Clinically relevant” bleeding is overwhelm-
ingly composed of nonmajor bleeds. Although such events reduce
patient persistence on anticoagulants, they are not comparable in
impact to major bleeds and have little role in the anticoagulation
decision. Trials of novel anticoagulant agents included nonmajor
bleeds in their safety endpoint to increase the sensitivity of detecting
a difference in bleeding risk versus VKAs, not because of the clinical
importance of these events. When Apostolakis et al. restricted their
analysis to major bleeding, the 3 schemes were similar in performance.
Importantly, there were only 39 major bleeding events in the VKA
arm. The authors do not report results from the idraparinux arm of
the AMADEUS trial although there were 2.5 times as many major
bleeds in that cohort (5). Precision is also a concern with the authors’
assertion that the HAS-BLED scheme predicted intracranial hemor-
rhage. Few details of this analysis are provided. The AMADEUS trial
reported only 9 intracranial hemorrhages in the VKA arm. Were the
authors’ analyses based on just 9 events?
HAS-BLED is distinctive in using “INR lability” as a predictor.
There are strong arguments against including international normal-
ized ratios (INRs) in bleeding risk–prediction schemes. First, there are
no INRs available to the patient considering starting VKAs and, second,
INRs are not applicable to novel anticoagulant agents. Furthermore, the
use by Apostolakis et al. (1) of INRs likely biases the data in favor of the
HAS-BLED score. For the HEMORR2HAGES and ATRIA scores,
he authors include only baseline predictor values but for HAS-
LED, they include postbaseline information (i.e., INR values).
very variable included in HAS-BLED is included in the
EMORR2HAGES scheme except for INR lability. Presumably, this
questionable use of postbaseline INR values accounts for the difference in
performance between the 2 schemes.
The bleeding risk–prediction schemes are multipoint scores. A
fair assessment would test the entire range of the point scores for
each scheme both for c-indexes and for Cox models.
More generally, the bleed risk-prediction schemes were
developed on AF cohorts in clinical care and meant to apply to
patients in clinical care. Clinical trials generally exclude patients
who have abnormal bleed score variables, thereby providing an
inadequate test of score performance. Empirically, 77% of patients
in AMADEUS had HEMORR2HAGES scores of 1, a mark-edly left-shifted distribution compared with the original
HEMORR2HAGES cohort (3).
Although the AMADEUS trial is suboptimal for assessing
leed risk–prediction schemes, the authors could begin to address
ur concerns by assessing performance in both the idraparinux and
KA arms in AMADEUS, excluding INR values, including the
ntire range of point scores for each risk scheme, and restricting
he endpoint to major hemorrhage.
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The Analysis of Bleeding
Risk–Prediction Scores
Should Include All Major Bleeds
The study by Apostolakis et al. (1) compares the performance of
bleeding risk–prediction scores in AMADEUS participants ran-
